Physician profile
Theodore E Margo
NPI 1780680892
$1,593.03
in general payments reported to CMS, 2019-2025
13 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $71.79 · 2021: $211 · 2022: $240 · 2023: $221 · 2024: $295 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $410.96 | 2019-2025 | Clareon, Dailies Total1 |
| Tarsus Pharmaceuticals, INC. | $307.42 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $262.28 | 2022-2024 | Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $138.03 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.75 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $121.71 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $80.71 | 2019 | |
| Rxsight INC | $53.35 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Carl Zeiss Meditec USA, INC. | $26.41 | 2022 | |
| Shire North American Group INC | $18.36 | 2019 | |
| Allergan, INC. | $18.17 | 2021 | |
| Thea Pharma INC. | $17.92 | 2024 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Margo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.